 Bennett Chin
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiopharmaceuticals | 25 | 2022 | 168 | 3.390 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 19 | 2014 | 77 | 2.310 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 99 | 1.690 |
Why?
| | Fluorodeoxyglucose F18 | 15 | 2019 | 128 | 1.620 |
Why?
| | Iodine Radioisotopes | 8 | 2023 | 142 | 1.380 |
Why?
| | Organometallic Compounds | 6 | 2023 | 106 | 1.350 |
Why?
| | Positron-Emission Tomography | 8 | 2024 | 282 | 1.120 |
Why?
| | Tomography, Emission-Computed | 9 | 2004 | 66 | 1.090 |
Why?
| | Image Enhancement | 4 | 2007 | 167 | 0.750 |
Why?
| | Heart | 8 | 2014 | 641 | 0.670 |
Why?
| | 3-Iodobenzylguanidine | 3 | 2023 | 7 | 0.650 |
Why?
| | Fluorine Radioisotopes | 3 | 2017 | 12 | 0.620 |
Why?
| | Thallium Radioisotopes | 5 | 1999 | 8 | 0.560 |
Why?
| | Radionuclide Imaging | 13 | 2022 | 122 | 0.550 |
Why?
| | Contrast Media | 6 | 2014 | 393 | 0.530 |
Why?
| | Urinary Retention | 1 | 2016 | 20 | 0.520 |
Why?
| | Positron Emission Tomography Computed Tomography | 5 | 2022 | 87 | 0.520 |
Why?
| | Carcinosarcoma | 1 | 2016 | 16 | 0.520 |
Why?
| | Leucine | 1 | 2017 | 109 | 0.510 |
Why?
| | Paraganglioma | 3 | 2023 | 49 | 0.510 |
Why?
| | Oxyquinoline | 2 | 2007 | 3 | 0.490 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 106 | 0.470 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 627 | 0.440 |
Why?
| | Whole Body Imaging | 2 | 2014 | 20 | 0.430 |
Why?
| | Gated Blood-Pool Imaging | 2 | 2007 | 5 | 0.430 |
Why?
| | Leukemia L1210 | 2 | 2012 | 7 | 0.430 |
Why?
| | Gallium Radioisotopes | 2 | 2023 | 14 | 0.420 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 30 | 0.380 |
Why?
| | Chloroquine | 1 | 2012 | 51 | 0.380 |
Why?
| | Technetium Tc 99m Sestamibi | 8 | 2016 | 12 | 0.360 |
Why?
| | Myocardial Infarction | 3 | 2007 | 1021 | 0.360 |
Why?
| | Phenylalanine | 1 | 2011 | 65 | 0.360 |
Why?
| | Isoenzymes | 1 | 2012 | 301 | 0.350 |
Why?
| | Thyroid Neoplasms | 3 | 2016 | 312 | 0.350 |
Why?
| | Prostatic Neoplasms | 3 | 2016 | 998 | 0.350 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2023 | 83 | 0.340 |
Why?
| | Pheochromocytoma | 2 | 2023 | 57 | 0.330 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2007 | 385 | 0.320 |
Why?
| | Coronary Circulation | 5 | 2002 | 138 | 0.320 |
Why?
| | Phantoms, Imaging | 7 | 2015 | 137 | 0.310 |
Why?
| | Electrocardiography | 2 | 2014 | 611 | 0.310 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2009 | 101 | 0.310 |
Why?
| | Tissue Distribution | 3 | 2017 | 315 | 0.310 |
Why?
| | Aldehydes | 1 | 2009 | 143 | 0.300 |
Why?
| | Sensitivity and Specificity | 7 | 2017 | 1843 | 0.300 |
Why?
| | Radiation Dosage | 3 | 2015 | 154 | 0.290 |
Why?
| | Breast Neoplasms | 3 | 2017 | 2133 | 0.280 |
Why?
| | Lung Neoplasms | 3 | 2016 | 2342 | 0.280 |
Why?
| | Tomography, X-Ray Computed | 7 | 2008 | 2512 | 0.270 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2005 | 252 | 0.260 |
Why?
| | Bone Marrow Cells | 1 | 2007 | 302 | 0.250 |
Why?
| | Gamma Cameras | 1 | 2005 | 7 | 0.240 |
Why?
| | Bone Marrow Transplantation | 1 | 2007 | 277 | 0.240 |
Why?
| | Radiometry | 2 | 2017 | 47 | 0.240 |
Why?
| | Feasibility Studies | 6 | 2009 | 869 | 0.240 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2004 | 958 | 0.240 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2006 | 72 | 0.240 |
Why?
| | Intercostal Muscles | 1 | 2004 | 3 | 0.230 |
Why?
| | Humans | 45 | 2024 | 129627 | 0.230 |
Why?
| | Indium Radioisotopes | 3 | 1999 | 13 | 0.230 |
Why?
| | Stomach Neoplasms | 2 | 2022 | 98 | 0.230 |
Why?
| | Data Curation | 1 | 2024 | 11 | 0.220 |
Why?
| | Somatostatin | 3 | 2016 | 56 | 0.220 |
Why?
| | Vocal Cord Paralysis | 1 | 2003 | 29 | 0.210 |
Why?
| | Vocal Cords | 1 | 2003 | 32 | 0.210 |
Why?
| | Thyrotropin | 1 | 2004 | 109 | 0.210 |
Why?
| | Digestive System Neoplasms | 1 | 2003 | 8 | 0.210 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2003 | 51 | 0.210 |
Why?
| | Carcinoma, Papillary | 1 | 2003 | 77 | 0.210 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2002 | 15 | 0.200 |
Why?
| | Myocardial Contraction | 2 | 2002 | 335 | 0.200 |
Why?
| | Atherosclerosis | 1 | 2007 | 402 | 0.200 |
Why?
| | Radioisotopes | 1 | 2022 | 31 | 0.200 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2022 | 7 | 0.200 |
Why?
| | Receptors, Peptide | 1 | 2022 | 17 | 0.200 |
Why?
| | Myocardial Stunning | 1 | 2002 | 5 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 8 | 2022 | 3394 | 0.190 |
Why?
| | Dobutamine | 1 | 2002 | 37 | 0.190 |
Why?
| | Intestinal Neoplasms | 1 | 2022 | 28 | 0.190 |
Why?
| | Cell Line, Tumor | 3 | 2017 | 3186 | 0.190 |
Why?
| | Animals | 18 | 2019 | 35391 | 0.180 |
Why?
| | Mice | 8 | 2019 | 16961 | 0.170 |
Why?
| | Oxygen Consumption | 1 | 2003 | 672 | 0.160 |
Why?
| | Technetium Tc 99m Aggregated Albumin | 2 | 1999 | 6 | 0.160 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 1999 | 37 | 0.160 |
Why?
| | Stem Cells | 1 | 2003 | 575 | 0.160 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 1999 | 10 | 0.160 |
Why?
| | Receptors, Somatostatin | 1 | 1999 | 24 | 0.160 |
Why?
| | Female | 27 | 2018 | 68735 | 0.150 |
Why?
| | Thymus Neoplasms | 1 | 1999 | 22 | 0.150 |
Why?
| | Hormone Antagonists | 1 | 1999 | 33 | 0.150 |
Why?
| | Thymoma | 1 | 1999 | 33 | 0.150 |
Why?
| | Image Processing, Computer-Assisted | 4 | 2024 | 740 | 0.150 |
Why?
| | Radiation Pneumonitis | 1 | 1999 | 28 | 0.150 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1999 | 123 | 0.150 |
Why?
| | Metal Nanoparticles | 1 | 2019 | 81 | 0.150 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 1998 | 68 | 0.150 |
Why?
| | Sodium Pertechnetate Tc 99m | 1 | 1997 | 6 | 0.150 |
Why?
| | Cardiac Surgical Procedures | 1 | 2003 | 506 | 0.140 |
Why?
| | Middle Aged | 19 | 2016 | 31136 | 0.140 |
Why?
| | Pancreatic Neoplasms | 2 | 2022 | 880 | 0.140 |
Why?
| | Dipyridamole | 2 | 2002 | 28 | 0.140 |
Why?
| | Coronary Disease | 2 | 2000 | 385 | 0.140 |
Why?
| | Myocardium | 1 | 2003 | 980 | 0.140 |
Why?
| | Hematoma | 1 | 1997 | 53 | 0.140 |
Why?
| | Frontal Lobe | 1 | 1998 | 154 | 0.140 |
Why?
| | Isotope Labeling | 2 | 2011 | 74 | 0.140 |
Why?
| | Male | 24 | 2018 | 63671 | 0.140 |
Why?
| | Neoplasms | 1 | 2012 | 2455 | 0.140 |
Why?
| | Smoking | 1 | 2004 | 1500 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 544 | 0.130 |
Why?
| | Brain Neoplasms | 2 | 2019 | 1145 | 0.130 |
Why?
| | Transurethral Resection of Prostate | 1 | 2016 | 3 | 0.130 |
Why?
| | Safety | 1 | 2018 | 335 | 0.130 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 325 | 0.130 |
Why?
| | Vasodilator Agents | 2 | 2002 | 326 | 0.120 |
Why?
| | Parathyroid Diseases | 1 | 2015 | 1 | 0.120 |
Why?
| | Molecular Structure | 1 | 2017 | 481 | 0.120 |
Why?
| | Dementia | 1 | 1998 | 225 | 0.120 |
Why?
| | Thyroid Nodule | 1 | 2016 | 56 | 0.120 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2015 | 29 | 0.120 |
Why?
| | Sarcoidosis | 1 | 1997 | 156 | 0.120 |
Why?
| | Androstenes | 1 | 2015 | 17 | 0.120 |
Why?
| | Stroke Volume | 2 | 1997 | 592 | 0.120 |
Why?
| | Phenylthiohydantoin | 1 | 2015 | 41 | 0.120 |
Why?
| | Ventricular Function, Right | 1 | 1997 | 276 | 0.120 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2015 | 71 | 0.120 |
Why?
| | Taxoids | 1 | 2015 | 98 | 0.110 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 45 | 0.110 |
Why?
| | Mediastinum | 1 | 2014 | 24 | 0.110 |
Why?
| | Dogs | 4 | 2003 | 383 | 0.110 |
Why?
| | Prednisone | 1 | 2015 | 234 | 0.110 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1250 | 0.110 |
Why?
| | Ventricular Function, Left | 1 | 1997 | 528 | 0.110 |
Why?
| | Coronary Stenosis | 3 | 2002 | 39 | 0.110 |
Why?
| | Cardiomyopathies | 1 | 1997 | 340 | 0.100 |
Why?
| | Bone and Bones | 3 | 2009 | 294 | 0.100 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 99 | 0.100 |
Why?
| | Healthy Volunteers | 1 | 2014 | 201 | 0.100 |
Why?
| | Carbon Radioisotopes | 1 | 2011 | 34 | 0.090 |
Why?
| | Swine | 6 | 2003 | 764 | 0.090 |
Why?
| | Hemodynamics | 1 | 1996 | 1090 | 0.090 |
Why?
| | Time Factors | 2 | 2014 | 6555 | 0.090 |
Why?
| | Lymph Nodes | 2 | 2003 | 472 | 0.090 |
Why?
| | Organ Specificity | 2 | 2019 | 296 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2015 | 752 | 0.090 |
Why?
| | Neoplasm Metastasis | 2 | 2004 | 611 | 0.090 |
Why?
| | Aged | 11 | 2015 | 22061 | 0.090 |
Why?
| | Adult | 12 | 2014 | 35600 | 0.090 |
Why?
| | Thyroid Gland | 2 | 2016 | 95 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2007 | 3080 | 0.080 |
Why?
| | Mice, Nude | 1 | 2012 | 682 | 0.080 |
Why?
| | Gadolinium | 4 | 2002 | 78 | 0.080 |
Why?
| | K562 Cells | 1 | 2009 | 85 | 0.080 |
Why?
| | Blotting, Western | 1 | 2012 | 1206 | 0.080 |
Why?
| | Metabolic Clearance Rate | 1 | 2008 | 117 | 0.080 |
Why?
| | Glioblastoma | 1 | 2012 | 322 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2007 | 5455 | 0.070 |
Why?
| | Parathyroid Neoplasms | 2 | 1997 | 13 | 0.070 |
Why?
| | Octreotide | 2 | 1999 | 27 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2002 | 1282 | 0.070 |
Why?
| | Adenoma | 3 | 1998 | 214 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 2046 | 0.070 |
Why?
| | Injections, Intravenous | 2 | 2003 | 202 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 333 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2016 | 14522 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1293 | 0.060 |
Why?
| | Molecular Probe Techniques | 1 | 2005 | 9 | 0.060 |
Why?
| | Miniaturization | 1 | 2005 | 23 | 0.060 |
Why?
| | Molecular Biology | 1 | 2005 | 56 | 0.060 |
Why?
| | Iodides | 1 | 2004 | 6 | 0.060 |
Why?
| | Equipment Failure Analysis | 1 | 2005 | 130 | 0.060 |
Why?
| | Theophylline | 1 | 2004 | 68 | 0.060 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2004 | 89 | 0.060 |
Why?
| | Models, Animal | 2 | 2003 | 378 | 0.060 |
Why?
| | Biomarkers, Tumor | 2 | 2023 | 1164 | 0.060 |
Why?
| | Thyroglobulin | 1 | 2004 | 27 | 0.050 |
Why?
| | Equipment Design | 1 | 2005 | 514 | 0.050 |
Why?
| | Artifacts | 1 | 2004 | 126 | 0.050 |
Why?
| | Neck | 1 | 2003 | 95 | 0.050 |
Why?
| | Metanephrine | 1 | 2023 | 2 | 0.050 |
Why?
| | Inhalation | 1 | 2003 | 28 | 0.050 |
Why?
| | Exhalation | 1 | 2003 | 39 | 0.050 |
Why?
| | Chromogranin A | 1 | 2023 | 42 | 0.050 |
Why?
| | Gadolinium DTPA | 1 | 2002 | 51 | 0.050 |
Why?
| | Movement | 1 | 2004 | 270 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2015 | 7052 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 1005 | 0.040 |
Why?
| | Myocardial Ischemia | 1 | 2002 | 259 | 0.040 |
Why?
| | Intestines | 1 | 2004 | 347 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1308 | 0.040 |
Why?
| | Radioimmunodetection | 1 | 1999 | 1 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2007 | 2881 | 0.040 |
Why?
| | Esophageal Neoplasms | 1 | 2003 | 297 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2003 | 1109 | 0.040 |
Why?
| | Organotechnetium Compounds | 1 | 1998 | 10 | 0.040 |
Why?
| | Cell Movement | 1 | 2003 | 948 | 0.040 |
Why?
| | Bone Neoplasms | 2 | 1999 | 229 | 0.040 |
Why?
| | Pleural Neoplasms | 1 | 1999 | 24 | 0.040 |
Why?
| | Salvage Therapy | 1 | 1999 | 136 | 0.040 |
Why?
| | Optical Imaging | 1 | 2019 | 56 | 0.040 |
Why?
| | Mediastinal Neoplasms | 1 | 1999 | 38 | 0.040 |
Why?
| | Pilot Projects | 1 | 2003 | 1592 | 0.040 |
Why?
| | Gardner Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
| | Osteoma | 1 | 1998 | 2 | 0.040 |
Why?
| | Prostate-Specific Antigen | 2 | 2015 | 160 | 0.040 |
Why?
| | Gold | 1 | 2019 | 118 | 0.040 |
Why?
| | Retroperitoneal Space | 1 | 1997 | 16 | 0.040 |
Why?
| | Carcinoid Tumor | 1 | 1997 | 24 | 0.040 |
Why?
| | Duodenal Neoplasms | 1 | 1997 | 21 | 0.040 |
Why?
| | Cardiac Volume | 1 | 1997 | 12 | 0.040 |
Why?
| | HIV-1 | 1 | 2003 | 838 | 0.030 |
Why?
| | Cysteine | 1 | 1998 | 195 | 0.030 |
Why?
| | Ventricular Function | 1 | 1997 | 61 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 1998 | 228 | 0.030 |
Why?
| | Choristoma | 1 | 1996 | 21 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2007 | 4078 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 1999 | 212 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 698 | 0.030 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 1997 | 185 | 0.030 |
Why?
| | Colorectal Neoplasms | 1 | 2003 | 749 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 80 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1269 | 0.030 |
Why?
| | Deoxyglucose | 1 | 1995 | 52 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 1995 | 35 | 0.030 |
Why?
| | Radiography | 2 | 2015 | 797 | 0.030 |
Why?
| | Abiraterone Acetate | 1 | 2015 | 14 | 0.030 |
Why?
| | Kallikreins | 1 | 2015 | 29 | 0.030 |
Why?
| | Lung | 2 | 1999 | 3938 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1432 | 0.030 |
Why?
| | Benzamides | 1 | 2015 | 203 | 0.030 |
Why?
| | Nitriles | 1 | 2015 | 170 | 0.030 |
Why?
| | Infusions, Intra-Arterial | 1 | 1993 | 53 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 646 | 0.030 |
Why?
| | Infusion Pumps, Implantable | 1 | 1993 | 22 | 0.030 |
Why?
| | Hepatic Artery | 1 | 1993 | 59 | 0.030 |
Why?
| | Risk Factors | 3 | 2015 | 9786 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 1999 | 4894 | 0.030 |
Why?
| | Exercise Test | 1 | 1996 | 613 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 1999 | 1366 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 1996 | 520 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 851 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2018 | 10219 | 0.020 |
Why?
| | Erythrocytes | 1 | 1997 | 673 | 0.020 |
Why?
| | Biopsy | 1 | 2016 | 1088 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1198 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 3774 | 0.020 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1999 | 1049 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2564 | 0.020 |
Why?
| | HIV Infections | 1 | 2003 | 2730 | 0.020 |
Why?
| | Case-Control Studies | 1 | 1996 | 3378 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2641 | 0.020 |
Why?
| | Brain | 1 | 1999 | 2673 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2627 | 0.020 |
Why?
| | Risk Assessment | 1 | 2015 | 3262 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2004 | 23 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 2004 | 34 | 0.010 |
Why?
| | Adolescent | 2 | 2018 | 20412 | 0.010 |
Why?
| | Cyclic AMP | 1 | 2004 | 238 | 0.010 |
Why?
| | Diagnostic Errors | 1 | 2004 | 162 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2003 | 119 | 0.010 |
Why?
| | Viremia | 1 | 2003 | 131 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2002 | 171 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 949 | 0.010 |
Why?
| | Virus Replication | 1 | 2003 | 452 | 0.010 |
Why?
| | Coronary Vessels | 1 | 2002 | 239 | 0.010 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2000 | 140 | 0.010 |
Why?
| | Prostatectomy | 1 | 1999 | 103 | 0.010 |
Why?
| | Vasodilation | 1 | 2002 | 476 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 2004 | 590 | 0.010 |
Why?
| | Influenza Vaccines | 1 | 2003 | 532 | 0.010 |
Why?
| | Zollinger-Ellison Syndrome | 1 | 1997 | 2 | 0.010 |
Why?
| | Gastrins | 1 | 1997 | 9 | 0.010 |
Why?
| | Radionuclide Angiography | 1 | 1997 | 5 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4084 | 0.010 |
Why?
| | Research Design | 1 | 2002 | 1045 | 0.010 |
Why?
| | Esophagus | 1 | 1996 | 248 | 0.010 |
Why?
| | Heart Diseases | 1 | 1997 | 352 | 0.010 |
Why?
| | Technetium | 1 | 1993 | 12 | 0.010 |
Why?
| | Microspheres | 1 | 1993 | 124 | 0.010 |
Why?
| | Liver | 1 | 1993 | 1842 | 0.000 |
Why?
| | Prospective Studies | 1 | 1993 | 7135 | 0.000 |
Why?
|
|
Chin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|